Key Highlights

  • Hikma Pharmaceuticals Plc (LSE:HIK) climbed 2.42% on 6 October 2026, supported by steady Demand for quality healthcare names.
  • First-half 2026 core operating profit rose 9% to $405 million on Revenue up 4% to $1,728 million.
  • Branded revenue grew 15% in the first half, and the Business is expected to grow at the top end of its 6% to 8% guidance range.
  • The $250 million share buyback had reached $227 million by early August, and the Interim Dividend rose 6% to 38 cents.
  • Full-year guidance was reiterated, with core operating profit expected between $720 million and $770 million.

Hikma Pharmaceuticals Plc (LSE:HIK) Moves Higher

Hikma Pharmaceuticals Plc (LSE:HIK) rose 2.42% on Tuesday, 6 October 2026, as investors added exposure to the multinational pharmaceutical group. Hikma manufactures and sells generic, branded and injectable medicines across the United States, the Middle East and North Africa and Europe, and has been on a positive trajectory since its interim results in August, when the shares jumped close to 9% in a single session.

Tuesday's gain came on a broadly positive day for European equities, with markets lifted by gains on Wall Street and softer crude prices. For Hikma Pharmaceuticals Plc (LSE:HIK), a weaker oil price can also be a positive signal for sentiment in its Middle East and North Africa markets, where economic stability supports healthcare spending.

Why Hikma Pharmaceuticals Plc (LSE:HIK) Is in Focus

The main reason Hikma Pharmaceuticals Plc (LSE:HIK) is attracting attention is the strength of its Branded business. In the first half of 2026, branded revenue grew 15%, supported by strong performance in key markets such as Saudi Arabia, a focus on medicines used to treat chronic illnesses and improved capacity to respond to market opportunities. The company now expects branded revenue to grow at the top end of its 6% to 8% guidance range for the full year.

Group revenue rose 4% to $1,728 million, while core operating profit increased 9% to $405 million and core EBITDA climbed 8% to $463 million. Core Earnings Per Share improved to 128 cents from 122 cents. Operating Cash Flow rose 33% to $214 million. Reported operating profit increased 30% to $336 million, reflecting the absence of prior-year legal settlement costs.

Chief executive Said Darwazah said the first half was solid and in line with expectations, adding that he was encouraged by the positive momentum across the organisation. He highlighted new product launches, a strengthened pipeline, new partnerships and optimised Manufacturing operations as initiatives that will support long-term growth.

Shareholder Returns Are a Key Attraction

Hikma Pharmaceuticals Plc (LSE:HIK) has been returning significant Capital to shareholders. The $250 million share buyback programme, launched in February 2026, was progressing well, with $227 million worth of shares purchased by 5 August. The board also declared an interim dividend of 38 cents per share, up 6% from 36 cents.

Net Debt to core EBITDA stood at 1.9 times, up from 1.6 times at the end of 2025, reflecting the buyback and Investment activity. That Leverage level remains comfortable for a business with Hikma's cash generation, leaving room for further investment or Shareholder returns.

Full-Year Guidance Reiterated

Management reiterated full-year guidance, expecting group revenue growth of 2% to 4% in constant currency and core operating profit of $720 million to $770 million, compared with $741 million in 2025. Guidance is provided in constant currency. Meeting or beating this guidance would demonstrate the resilience of Hikma's diversified model, with Branded growth offsetting more competitive dynamics in parts of the US generics market.

The company has also been investing in its injectables platform, which is one of its most important businesses in the United States. Injectable medicines are often supplied to hospitals and are subject to periodic shortages, which can create opportunities for reliable manufacturers like Hikma.

Why the Stock Moved Up Today

The 2.42% gain in Hikma Pharmaceuticals Plc (LSE:HIK) on 6 October reflected a supportive market backdrop, continued confidence in the company's guidance and steady demand for quality healthcare stocks with predictable cash flows. Investors seeking a mix of defensive characteristics and growth have been attracted to Hikma's combination of Branded expansion, shareholder returns and reasonable valuation. The completion of the buyback also continues to support the share count and earnings per share.

What Investors Are Watching Next

Investors will be watching for any update on the buyback once the current programme completes, new product launches in the US injectables and generics businesses, and progress in the Branded business across the Middle East and North Africa. The company's next trading update, usually provided around the turn of the year, will be watched for confirmation of the full-year outlook. US healthcare policy, including tariffs and drug pricing reforms, remains an important external factor.

Risks include pricing pressure in US generics, regulatory issues at manufacturing sites, currency Volatility in emerging markets and geopolitical tensions in the Middle East. Nevertheless, with solid first-half results, reaffirmed guidance and continued shareholder returns, Hikma Pharmaceuticals Plc (LSE:HIK) remains a core holding for many investors seeking exposure to global healthcare.